Update on prostate cancer chemoprevention

Pharmacotherapy

Volumn 26, Issue 3, 2006, Pages 353-359

  Lowe, Jennifer Fisher ^a   Frazee, Lawrence A ^a,b  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

5 reductase inhibitors; Chemoprevention; Dutasteride; Finasteride; PCPT; Prostate cancer; REDUCE trial; SELECT

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BETA CAROTENE; CAROTENOID; DUTASTERIDE; FINASTERIDE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; VITAMIN;

BLOOD LEVEL; CANCER PREVENTION; CANCER RISK; CAUSE OF DEATH; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; HUMAN; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZASTEROIDS; CAROTENOIDS; CHEMOPREVENTION; CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; SELENIUM; TESTOSTERONE 5-ALPHA-REDUCTASE; VITAMIN E; VITAMINS;

EID: 33644680179     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.3.353     Document Type: Review

References (48)

1. American Cancer Society. Cancer facts and figures, April 2005. Available from www.cancer.org/docroot/STT/stt_0.asp. Accessed April 21, 2005.
2. The National Comprehensive Cancer Network. Prostate cancer, April 2005. Available from http://www.nccn.org/ professionals/physician_gls/PDF/prostate. pdf. Accessed April 22, 2005.
3. National Cancer Institute. Prostate cancer, April 2005. Available from http://www.cancer.gov/cancertopics/types/ prostate. Accessed April 22, 2005.
4. Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-Reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet 1992;339:887-9.
5. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
6. Thompson I, Carroll P, Coley C, et al, for the PSA Best Practice Policy Task Force. Prostate specific antigen (PSA) best practice policy: American Urological Association (AUA). Oncology 2000;14:267-72.
7. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-202.
8. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
9. Garzotto M, Beer TM, Hudson RG, et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005;23:1-8.
10. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic diseases. JAMA 1998;279:1542-7.
11. Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997;24:339-51.
12. American Cancer Society. ACS cancer detection guidelines, June 2005. Available from http://www.cancer.org/docroot/PED/ content/ PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp. Accessed June 9, 2005.
13. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21(6 suppl):251S-72.
14. de Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening power and time frame with complete enrollment in the European randomized screening for prostate cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.
15. Brawley OW. The potential for prostate cancer chemoprevention. Urology 2002;4(5 suppl):S11-17.
16. Fisher B, Costantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst 1998;90:1371-88.
17. Gupta S. Prostate cancer chemoprevention: models, limitations, and potential. Int J Oncol 2004;25:1133-48.
18. Edwards A, Vinyard B, Wiley E, et al. Consumption of watermelon juice increases plasma concentrations of lycopene and beta carotene in humans. J Nutr 2003;133:1043-50.
19. Karas M, Amir H, Fishman D, et al. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cells. Nutr Cancer 2000;36:101-11.
20. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am J Epidemiol 2000;151:119-23.
21. Giovannucci E, Ascherio A, Rimm E, Stampfer M, Colditz G, Willet W. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-76.
22. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
23. Gann PH, Ma J, Giofannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-30.
24. Cook NR, Stampfer MJ, Ma J, et al. β-Carotene supplementation for patients with low baseline levels and decreased risk of total prostate carcinoma. Cancer 1999;86:1783-92.
25. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of α-tocopherol and -carotene supplements on cancer incidence in the a-tocopherol β-carotene cancer prevention study. Am J Clin Nutr 1995;62(6 suppl):1427S-30.
26. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8.
27. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advance prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
28. Nomura AM, Lee J, Stemmermann GN, Combs GF. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
29. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial. BJU Int 2003;91:608-12.
30. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. J Urol 2001;166:1311-15.
31. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate carcinoma. Prostate 2000;42:73-8.
32. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-41.
33. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: an overview of United States trials. J Urol 2004;171(suppl):S5-9.
34. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-70.
35. Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1108-11.
36. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-9.
37. Harris RE, Beebe-Donk J, Doss H, Doss DB. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005;13:559-83.
38. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
39. Thomas LN, Douglas RC, Vessey JP, et al. 5-α Reductase type 1 immunostaining is enhanced in prostate cancer tissue compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019-25.
40. Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143-9.
41. Djavan B, Zlotta A, Schulman C, et al. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004;171:S10-14.
42. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
43. Gomella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29-32.
44. Scardino PT. The prevention of prostate cancer: the dilemma continues. N Engl J Med 2003;349:297-9.
45. Higgins B, Thompson IM. The prostate cancer prevention trial: current status. J Urol 2004;171:S15-18.
46. Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005;23:368-77.
47. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-α-reductase inhibitor. J Clin Endocrinol Metab 2004;89: 2179-84.
48. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention on prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-17.